Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis

Nephrol Dial Transplant. 2012 Oct;27(10):3823-8. doi: 10.1093/ndt/gfr773. Epub 2012 Jan 23.


Background: To determine the efficacy of immunoglobulin free light chain (FLC) removal by high cut-off haemodialysis (HCO-HD) as an adjuvant treatment to chemotherapy for patients with acute kidney injury complicating multiple myeloma (MM).

Methods: Sixty-seven patients with dialysis-dependent renal failure secondary to MM were treated with HCO-HD and chemotherapy.

Results: The population was predominantly male (62.7%) with new presentation MM (75%) and did not have a history of chronic kidney disease (84%). The mean serum creatinine at presentation was 662 (SD = 349) μmol/L and of the 56.7% of patients who had a renal biopsy, 86.7% had cast nephropathy as the principal diagnosis. Eighty-five percent of patients were treated with a chemotherapy regime consisting of dexamethasone in combination with a novel agent (bortezomib or thalidomide). The median number of HCO-HD sessions was 11 (range 3-45), 97% received an extended dialysis regime. Seventy-six percent of the population had a sustained reduction in serum FLC concentrations by Day 12, of these 71% subsequently became independent of dialysis. In total, 63% of population became independent of dialysis. Factors which predicted independence of dialysis were the degree of FLC reduction at Days 12 (P = 0.002) and 21 (P = 0.005) and the time to initiating HCO-HD (P = 0.006).

Conclusion: The combination of extended HCO-HD and chemotherapy resulted in sustained reductions in serum FLC concentrations in the majority of patients and a high rate of independence of dialysis.

Publication types

  • Multicenter Study

MeSH terms

  • Acute Kidney Injury / etiology*
  • Acute Kidney Injury / immunology
  • Acute Kidney Injury / therapy*
  • Aged
  • Boronic Acids / administration & dosage
  • Bortezomib
  • Combined Modality Therapy
  • Databases, Factual
  • Dexamethasone / administration & dosage
  • Female
  • Humans
  • Immunoglobulin Light Chains / blood*
  • Immunoglobulin Light Chains / isolation & purification
  • Male
  • Middle Aged
  • Multiple Myeloma / complications*
  • Multiple Myeloma / immunology
  • Multiple Myeloma / therapy*
  • Pyrazines / administration & dosage
  • Renal Dialysis / methods*
  • Thalidomide / administration & dosage


  • Boronic Acids
  • Immunoglobulin Light Chains
  • Pyrazines
  • Thalidomide
  • Bortezomib
  • Dexamethasone